Date | Title | Description | |
---|---|---|---|
27 Feb 2024 | On P&L | The Company releases the press release related to the full year 2023 financial results. | Download |
27 Feb 2024 | On P&L | The Company releases the full year 2023 financial results presentation. | Download |
27 Feb 2024 | About Corporate Governance | The Company informs about the agreements adopted by the Board of Directors | Download |
08 Nov 2023 | On P&L | The Company releases the press release related to the first nine months of 2023 financial results | Download |
08 Nov 2023 | On P&L | The Company releases the first nine months 2023 financial results presentation | Download |
Pages
Date | Title | Description | |
---|---|---|---|
05 Apr 2024 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 28 March and 4 April 2024 | Download |
02 Apr 2024 | On business and financial situation | ROVI informs on the FDA’s approval of Risvan® as a treatment for schizophrenia | Download |
29 Mar 2024 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 22 March and 27 March 2024 | Download |
22 Mar 2024 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 15 March and 21 March 2024 | Download |
15 Mar 2024 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 8 March and 14 March 2024 | Download |
Pages
Date | Title | Description | |
---|---|---|---|
08 Jan 2018 | Contratos de liquidez y contrapartida | Liquidity contract: transactions conducted in the fourth quarter of 2017 | Download |
21 Dec 2017 | Préstamos, créditos y avales | ROVI and the EIB agree to sign a loan to boost research into drug administration and prolonged-release technologies | Download |
08 Nov 2017 | Información sobre Resultados | ROVI releases the press release related to the nine-month period ended 30 September 2017 results | Download |
08 Nov 2017 | Información sobre Resultados | ROVI releases the presentation related to the nine-month period ended 30 September 2017 results. | Download |
24 Oct 2017 | Otros sobre negocio y situación financiera | The Company releases the presentation related to the update of its Phase III-Prima 3 Risperidone ISM® project. | Download |